AGE — Agex Therapeutics Share Price
Last Trade - 00:00- $39.91m
- $46.41m
- $1.41m
Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | |||
| EPS Growth (f) | |||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | |||
| Price to Tang. Book | |||
| Price to Free Cashflow | |||
| Price to Sales | |||
| EV to EBITDA | |||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | |||
| Return on Equity | |||
| Operating Margin | |||
Financial Summary
| Year End 31st Dec | Unit | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 1.67 | 1.4 | 1.4 | 1.73 | 1.87 | n/a | n/a | 2.9% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health trend(F-Score)
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
AgeX Therapeutics Inc. is a biotechnology company. The Company is focused on the development and commercialization of therapeutics targeting human aging. Its induced Tissue Regeneration (iTR) technology is based telomerase-mediated cellular immortality and regenerative biology. Its pipeline includes two cell-based, two drug-based therapeutic products, online database products and research products. The Company’s AGEX-BAT1 is its cell therapy product candidate that is being developed for the treatment of certain age-related metabolic disorders, such as Type II (adult-onset) diabetes. AGEX-VASC1 is its cell-based therapy that is designed to restore vascular support in aged ischemic tissues such as the aging heart. AGEX-iTR1547 is its drug-based formulation developed to restore regenerative potential in an array of aged tissues afflicted with degenerative disease using its proprietary iTR technology. Renelon is its iTR product candidate designed to promote scar less tissue repair.
Directors
- Gregory Bailey NEC (65)
- Michael West (66)
- Andrea Park
- Nafees Malik (42)
- Hal Sternberg (66)
- Annalisa Jenkins (55)
- Michael May (51)
- Last Annual
- December 31st, 2020
- Last Interim
- March 31st, 2021
- Incorporated
- January 6th, 2017
- Public Since
- November 29th, 2018
- No. of Shareholders
- 241
- No. of Employees
- 6
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NYSE MKT
- Shares in Issue
- 37,935,088
- Address
- 965 Atlantic Ave Ste 101, ALAMEDA, 94501-1079
- Web
- http://www.agexinc.com
- Phone
- +1 5106718370
- Auditors
- OUM & CO. LLP
Latest News for AGE
Upcoming events for AGE
Q3 2021 AgeX Therapeutics Inc Earnings Release
Similar to AGE
ACTINIUM PHARMACEUTICALS ORD
NYSE MKT
AIM IMMUNOTECH ORD
NYSE MKT
AMPIO PHARMACEUTICALS ORD
NYSE MKT
ANNOVIS BIO ORD
NYSE MKT
BIOMX ORD
NYSE MKT
FAQ
As of Today at 19:57 UTC, shares in Agex Therapeutics are trading at $1.05. This share price information is delayed by 15 minutes.
Shares in Agex Therapeutics last closed at $1.05 and the price had moved by -4.36% over the past 365 days. In terms of relative price strength the Agex Therapeutics share price has underperformed the S&P500 Index by -27.44% over the past year.
There is no consensus recommendation for this security.
Agex Therapeutics does not currently pay a dividend.
Agex Therapeutics does not currently pay a dividend.
Agex Therapeutics does not currently pay a dividend.
To buy shares in Agex Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $1.05, shares in Agex Therapeutics had a market capitalisation of $39.91m.
Here are the trading details for Agex Therapeutics:
- Country of listing: United States
- Exchange: ASQ
- Ticker Symbol: AGE
Based on an overall assessment of its quality, value and momentum Agex Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Agex Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -60.86%.
As of the last closing price of $1.05, shares in Agex Therapeutics were trading -35.74% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We are not able to find PE ratio data for Agex Therapeutics.
Agex Therapeutics' management team is headed by:
- Gregory Bailey - NEC
- Michael West -
- Andrea Park -
- Nafees Malik -
- Hal Sternberg -
- Annalisa Jenkins -
- Michael May -
We do not have data on Agex Therapeutics' shareholders